Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||FT538 + Trastuzumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|FT538||FT-538|FT 538||FT538 consists of a preparation of natural killer cells derived from induced pluripotent stem cells engineered to lack CD38 and to express an IL-15 receptor alpha fusion protein and a non-cleavable form of CD16, which potentially induces enhanced antibody-dependent cellular cytotoxicity against tumor cells (Blood (2019) 134 (Supplement_1): 133).|
|Trastuzumab||Herceptin||Anti HER2||HER2 (ERBB2) Antibody 63||Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05069935||Phase I||Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine||FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors||Terminated||USA||0|